About
IR-MED is developing a cutting-edge infrared spectroscopy and AI analysis technology platform as a basis for point-of-care decision support devices. The infrared spectroscopy technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue. Bioinformation is then analyzed using the company’s AI process to provide healthcare professionals with decision support in the detection and monitoring of various disease conditions.
PressureSafe, the company’s first product based on this platform, is a handheld device designed to revolutionize early detection of pressure injuries (PI) affecting skin and underlying tissue. Pressure Injury in the US alone accounts for $26.8B in healthcare spending and results in 60,000 deaths annually. PressureSafe is expected to contribute to early detection of pressure injuries, regardless of patient skin tone. This will drive equitable healthcare and help reduce the toll and cost of PI.
IR-MED holds patents protecting its innovation in noninvasive tissue analysis and in modeling and analysis of subcutaneous tissue.
Funding history · 2 rounds · $8.7M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did IR-MED become a public company and on which exchange?
- IR-MED became public on the OTCQB exchange in December 2020 through a reverse merger, followed by an IPO in January 2021.
- What was the total amount raised by IR-MED through funding rounds?
- IR-MED has raised a total of $8.73 million through funding rounds, including a Seed round and a PIPE round in April 2022.
- What is IR-MED's primary product and its purpose?
- IR-MED's primary product is PressureSafe, a handheld device that uses infrared spectroscopy and AI analysis for the early, non-invasive detection of pressure injuries (PI) in skin and underlying tissue, regardless of patient skin tone.
- Has IR-MED received any grants from the Israel Innovation Authority?
- Yes, IR-MED received a $500,000 grant from the Israel Innovation Authority in July 2024 to develop its platform technology for early detection of Diabetic Foot Ulcers, and another $500,000 grant in May 2025 to advance its AI-powered DiaSafe device for Diabetic Foot Ulcer assessment.
- What significant clinical milestone did IR-MED achieve for its PressureSafe device in February 2024?
- In February 2024, IR-MED reported 92% efficacy for its PressureSafe device in early, non-invasive, skin color agnostic detection of pressure injuries.
- Which healthcare system adopted IR-MED's PressureSafe device for a usability study in September 2024?
- Methodist Healthcare adopted IR-MED’s PressureSafe device for a usability study in September 2024, aiming to reduce the healthcare burden of pressure injuries.
- When did IR-MED receive FDA Listing for its PressureSafe device?
- IR-MED's PressureSafe device received FDA Listing for the indication of a Decision Support Device for Pressure Injuries in April 2024.
- What was the outcome of the usability study for IR-MED's PressureSafe device with Clalit, Israel's largest HMO?
- In May 2024, a usability study with Clalit, Israel's largest HMO, showed that IR-MED’s PressureSafe device reduced pressure injuries by 50%.
- When did IR-MED launch the first-in-human clinical trial for its DiaSafe device?
- IR-MED announced the launch of the first-in-human clinical trial of its DiaSafe™ device for Diabetic Foot Ulcer (DFU) assessment in November 2025.